Capricor Therapeutics has become one of the most closely watched small-cap biotechnology companies as the U.S. Food and Drug Administration approaches its decision on Deramiocel, an investigational therapy for Duchenne muscular dystrophy. The company’s shares surged sharply in after-hours trading in the attached market data, even as the regulatory backdrop remains highly uncertain following a 9-3 FDA advisory committee vote against the effectiveness evidence supporting the treatment.

FDA Review Remains Open After Advisory Vote

The July 29 advisory committee vote represented a major setback for Capricor, with committee members voting against the effectiveness data supporting Deramiocel. FDA staff had previously raised concerns about the strength of the clinical evidence and changes to statistical analysis methods used after the Phase 3 trial. Reuters reported that the panel’s concerns included questions over the robustness of the data and whether the results demonstrated sufficient evidence of clinical benefit.

However, the advisory committee’s recommendation does not legally bind the FDA. Capricor’s Biologics License Application remains under review, with the agency’s PDUFA target action date set for August 22, 2026. The FDA had resumed review of the application after Capricor submitted additional clinical data from the Phase 3 HOPE-3 study following a Complete Response Letter issued in 2025.

That distinction is central to the current market reaction. The advisory vote materially increases regulatory uncertainty, but it does not eliminate the possibility of approval. The final decision will ultimately depend on the FDA’s assessment of the complete submission rather than the committee vote alone.

Deramiocel Remains the Company’s Critical Asset

Deramiocel is designed to address both cardiac and skeletal-muscle complications associated with Duchenne muscular dystrophy. Capricor’s HOPE-3 Phase 3 trial reported statistically significant results on its primary Performance of the Upper Limb endpoint and its key cardiac endpoint, left ventricular ejection fraction. The company has argued that the totality of evidence supports the therapy’s potential clinical benefit.

The FDA and its advisory committee, however, have focused on the reliability and interpretation of that evidence. FDA briefing materials raised concerns regarding post-trial changes to outcome measurements and statistical methodology, while committee members questioned whether the available data established a sufficiently robust treatment effect

This creates a binary regulatory environment for Capricor. The company currently has no commercially approved product, meaning the future value of its lead program is closely tied to the FDA’s decision. Capricor itself has disclosed that its ability to generate product revenue and achieve profitability depends on successful development, regulatory approval and commercialization of Deramiocel.

Liquidity Provides a Buffer, But Regulatory Risk Dominates

Capricor’s financial position provides an important buffer while the regulatory process unfolds. The company reported approximately $279 million in cash, cash equivalents and marketable securities at the end of the first quarter of 2026, and management previously said that its liquidity was expected to support operations into the fourth quarter of 2027.

The attached market data shows Capricor shares closing at approximately $4.21 before moving to roughly $6.78 after hours, a rise of about 61% from the regular-session close. Such a move highlights the unusually high sensitivity of the stock to regulatory developments and expectations surrounding Deramiocel.

For investors in Israel and globally, the immediate focus is therefore the FDA’s August 22 decision. Beyond that date, the company’s financial trajectory will depend on whether Deramiocel receives approval, whether additional clinical evidence is requested, and how Capricor would finance and execute a potential commercial launch. The regulatory outcome will remain the dominant variable for the company’s valuation, while its cash position provides additional time to navigate whichever path the FDA ultimately establishes.